Axonics Takes on Medtronic in Sacral Neuromodulation for Bowel and Bladder Control

This article really demonstrated and did a very nice job in separating out the different types of anticholinergic medications and, specifically, the anticholinergic medications to treat overactive bladder, which is the primary pharmacological intervention that we have," Noblett said. The researchers analyzed the data by type of burden and level of burden (low, medium, high) and found that the risk of dementia, even in the low burden, went up by 19% and in the high burden was up by 60%.  "And those were just for patients with the overactive bladder anticholinergic," Noblett said. "So this study really has brought home a sort of definitive data about the relationship of dementia in the anticholinergic medications. And I think this will end up change in practice quite significantly as we go forward." And from a business standpoint, the timing of that publication couldn't have been better for Axonics. "Here we are entering a market, entering an existing market with a product that is long-lived and we are addressing a chronic problem with a long-lived device," Cohen said. "So I think that physicians will be very receptive, maybe even more so, to our message and to this device than they might have been given that one of the primary tools in their tool chest now looks to be something that most patients are not going to want to take." Medtronic and Axonics Won't be Alone for Long Given the potential market opport...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news